Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- RM 242 HIF-1-? ? alpha beta bHLHPAS bHLHe 78 MOP Basic-helix-loop-helix-PAS Protein MOP1 Class E Basic Helix-loop-helix Protein 78 HIF1a bHLHe78 Member of PAS Protein 1 PAS Domain-containing Protein 8 HIF1?
- Product Overview:
Hypoxia-Inducible Factor-1? (HIF-1?) is a transcription factor subunit that belongs to the basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) protein family.{11044,46550} It contains bHLH and PAS domains that mediate DNA binding and heterodimerization with the HIF-1? subunit, an oxygen-dependent degradation (ODD) domain that is hydroxylated by prolyl hydroxylase in the presence of oxygen to target HIF-1? for proteasomal degradation, and N- and C-terminal transactivation domains responsible for regulating the expression of HIF-1 target genes.{46550,46551} Under hypoxic conditions, HIF-1? is stabilized, accumulates in the cytoplasm, and is translocated to the nucleus where it forms a heterodimer with HIF-1? and induces the expression of genes involved in maintaining cellular oxygen homeostasis.{11044,46550,10948,12428} It is also involved in angiogenesis, glucose utilization, and pH regulation under hypoxic conditions, including in the tumor microenvironment.{17023} HIF-1? is overexpressed in a variety of cancer cell lines where it promotes survival of cancer cells and increases invasiveness under hypoxic conditions and, in vivo, overexpression is associated with aggressiveness and progression of various cancers and poor disease-free survival.{17023,9833,46552,46553} Homozygous knockout of HIF-1? is embryonic lethal due to disruptions in vascular development but conditional knockout models have demonstrated a role for HIF-1? in inflammation, immunity, and osteogenesis.{17023} Cayman’s HIF-1? (human) Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes HIF-1? at approximately 120 kDa from human samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.